Association between RASSF1A Promoter Methylation and Prostate Cancer: A Systematic Review and Meta-Analysis

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Pan, Jincheng ^a   Chen, Junxing ^a   Zhang, Bo ^a   Chen, Xu ^a   Huang, Bin ^a   Zhuang, Jintao ^a   Mo, Chengqiang ^a   Qiu, Shaopeng ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PROMOTER REGION; PROSTATE CANCER; PROTEIN METHYLATION; PYROSEQUENCING; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

CASE-CONTROL STUDIES; DNA METHYLATION; HUMANS; MALE; META-ANALYSIS AS TOPIC; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 84884493084     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075283     Document Type: Article

References (32)

1. Siegel R, Naishadham D, Jemal A, (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29. doi:10.3322/caac.20138. PubMed: 22237781.
2. Siegel R, Naishadham D, Jemal A, (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30. doi:10.3322/caac.21166. PubMed: 23335087.
3. Alers JC, Krijtenburg PJ, Vis AN, Hoedemaeker RF, Wildhagen MF, et al. (2001) Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies: early cancers may contain aggressive genetic features. Am J Pathol 158: 399-406. doi:10.1016/S0002-9440(10)63983-1. PubMed: 11159178.
4. van Leeuwen PJ, Connolly D, Gavin A, Roobol MJ, Black A, et al. (2010) Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit. Eur J Cancer 46: 377-383. doi:10.1016/j.ejca.2009.09.008. PubMed: 19804966.
5. Barbieri CE, Demichelis F, Rubin MA, (2012) Molecular genetics of prostate cancer: emerging appreciation of genetic complexity. Histopathology 60: 187-198. doi:10.1111/j.1365-2559.2011.04041.x. PubMed: 22212086.
6. Wu T, Giovannucci E, Welge J, Mallick P, Tang WY, et al. (2011) Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis. Br J Cancer 105: 65-73. doi:10.1038/bjc.2011.143. PubMed: 21654682.
7. Bastian PJ, Yegnasubramanian S, Palapattu GS, Rogers CG, Lin X, et al. (2004) Molecular biomarker in prostate cancer: the role of CpG island hypermethylation. Eur Urol 46: 698-708. doi:10.1016/j.eururo.2004.07.022. PubMed: 15548435.
8. Ongenaert M, Van Neste L, De Meyer T, Menschaert G, Bekaert S, et al. (2008) PubMeth: a cancer methylation database combining text-mining and expert annotation. Nucleic Acids Res 36: D842-D846. PubMed: 17932060.
9. Aryee MJ, Liu W, Engelmann JC, Nuhn P, Gurel M, et al. (2013) DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med 5: 169ra110. PubMed: 23345608.
10. Kim JH, Dhanasekaran SM, Prensner JR, Cao X, Robinson D, et al. (2011) Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res 21: 1028-1041. doi:10.1101/gr.119347.110. PubMed: 21724842.
11. Allen NP, Donninger H, Vos MD, Eckfeld K, Hesson L, et al. (2007) RASSF6 is a novel member of the RASSF family of tumor suppressors. Oncogene 26: 6203-6211. doi:10.1038/sj.onc.1210440. PubMed: 17404571.
12. Burbee DG, Forgacs E, Zöchbauer-Müller S, Shivakumar L, Fong K, et al. (2001) Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 93: 691-699. doi:10.1093/jnci/93.9.691. PubMed: 11333291.
13. Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, et al. (2001) Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene 20: 1509-1518. doi:10.1038/sj.onc.1204175. PubMed: 11313894.
14. Donninger H, Vos MD, Clark GJ, (2007) The RASSF1A tumor suppressor. J Cell Sci 120: 3163-3172. doi:10.1242/jcs.010389. PubMed: 17878233.
15. Jerónimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, et al. (2004) A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 10: 8472-8478. doi:10.1158/1078-0432.CCR-04-0894. PubMed: 15623627.
16. Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zöchbauer-Müller S, et al. (2002) Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 8: 514-519. PubMed: 11839671.
17. Bastian PJ, Ellinger J, Wellmann A, Wernert N, Heukamp LC, et al. (2005) Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res 11: 4097-4106. doi:10.1158/1078-0432.CCR-04-1832. PubMed: 15930345.
18. Bastian PJ, Palapattu GS, Yegnasubramanian S, Rogers CG, Lin X, et al. (2008) CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer. J Urol 179: 529-534; discussion 534-525 doi:10.1016/S0022-5347(08)61556-6. PubMed: 18076941.
19. Cho NY, Kim BH, Choi M, Yoo EJ, Moon KC, et al. (2007) Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. J Pathol 211: 269-277. doi:10.1002/path.2106. PubMed: 17139617.
20. Florl AR, Steinhoff C, Müller M, Seifert HH, Hader C, et al. (2004) Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br J Cancer 91: 985-994. PubMed: 15292941.
21. Hoque MO, Topaloglu O, Begum S, Henrique R, Rosenbaum E, et al. (2005) Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol 23: 6569-6575. doi:10.1200/JCO.2005.07.009. PubMed: 16170165.
22. Kang GH, Lee S, Lee HJ, Hwang KS, (2004) Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol 202: 233-240. doi:10.1002/path.1503. PubMed: 14743506.
23. Kawamoto K, Okino ST, Place RF, Urakami S, Hirata H, et al. (2007) Epigenetic modifications of RASSF1A gene through chromatin remodeling in prostate cancer. Clin Cancer Res 13: 2541-2548. doi:10.1158/1078-0432.CCR-06-2225. PubMed: 17473182.
24. Rouprêt M, Hupertan V, Catto JW, Yates DR, Rehman I, et al. (2008) Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. Int J Cancer 122: 952-956. doi:10.1002/ijc.23196. PubMed: 17960617.
25. Rouprêt M, Hupertan V, Yates DR, Catto JW, Rehman I, et al. (2007) Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin Cancer Res 13: 1720-1725. doi:10.1158/1078-0432.CCR-06-2467. PubMed: 17363525.
26. Singal R, Ferdinand L, Reis IM, Schlesselman JJ, (2004) Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease. Oncol Rep 12: 631-637. PubMed: 15289848.
27. Syeed N, Syed Sameer A, Hamid A, Shah ZA, Afroze D, et al. (2010) Promoter methylation profile of GSTP1 and RASSF1A in benign hyperplasia and metastatic prostate cancer patients in a Kashmiri population. Mol Med Rep 3: 883-887. PubMed: 21472330.
28. Vasiljević N, Wu K, Brentnall AR, Kim DC, Thorat MA, et al. (2011) Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. Dis Markers 30: 151-161. doi:10.1155/2011/157829. PubMed: 21694441.
29. Woodson K, Gillespie J, Hanson J, Emmert-Buck M, Phillips JM, et al. (2004) Heterogeneous gene methylation patterns among pre-invasive and cancerous lesions of the prostate: a histopathologic study of whole mount prostate specimens. Prostate 60: 25-31. doi:10.1002/pros.20013. PubMed: 15129426.
30. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, et al. (2004) Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 64: 1975-1986. doi:10.1158/0008-5472.CAN-03-3972. PubMed: 15026333.
31. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, et al. (2011) Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 3: 111ra121. PubMed: 22133722.
32. Roychowdhury S, Chinnaiyan AM, (2013) Advancing Precision Medicine for Prostate Cancer Through Genomics. J Clin Oncol, 31: 1866-73. PubMed: 23589550.